P-Glycoprotein 抗体
Our Local Distributor
北京 101111
Quick Overview for P-Glycoprotein 抗体 (ABIN967562)
抗原
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
产品特性
-
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing. -
纯化方法
- The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
-
亚型
- IgG2b
-
-
-
-
应用备注
- Positive control cells are available through special order
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 0.5 mg/mL
-
缓冲液
- Aqueous buffered solution containing ≤0.09 % sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C
-
储存方法
- Store undiluted at 4°C.
-
-
-
: "High-affinity monoclonal antibodies against P-glycoprotein." in: Clinical immunology and immunopathology, Vol. 76, Issue 1 Pt 1, pp. 44-51, (1995) (PubMed).
: "Clinical significance of multiple drug resistance in human cancers." in: Anticancer research, Vol. 10, Issue 5A, pp. 1297-302, (1990) (PubMed).
: "Expression of a multidrug resistance gene in human cancers." in: Journal of the National Cancer Institute, Vol. 81, Issue 2, pp. 116-24, (1989) (PubMed).
-
: "High-affinity monoclonal antibodies against P-glycoprotein." in: Clinical immunology and immunopathology, Vol. 76, Issue 1 Pt 1, pp. 44-51, (1995) (PubMed).
-
- P-Glycoprotein
-
背景
-
Reacts with a 170-180 kDa transmembrane glycoprotein (P-glycoprotein), a product of the multidrug resistance-1 (MDR1) gene. This glycoprotein is expressed on MDR positive cells and has been reported to be expressed on many normal tissues, such as adrenal glands and endothelium, in the brain and skin. P-glycoprotein is known to impart drug resistance to cells by pumping many anti-cancer drugs out of the cytoplasm. 17F9 antibody binds to the surface of the viable, unfixed MDR+ cell line, PMG-Y (please inquire), and is able to partially block the binding of UIC2 antibody (another MDR-specific monoclonal antibody). Immunoprecipitation application is reported, but not routinely tested in house.
Synonyms: MDR
抗原
-